nodes	percent_of_prediction	percent_of_DWPC	metapath
Baclofen—Chlorpropamide—type 2 diabetes mellitus	0.532	1	CrCtD
Baclofen—Chlorpropamide—Tolazamide—type 2 diabetes mellitus	0.062	0.182	CrCrCtD
Baclofen—Chlorpropamide—Glimepiride—type 2 diabetes mellitus	0.062	0.182	CrCrCtD
Baclofen—Chlorpropamide—Gliclazide—type 2 diabetes mellitus	0.0588	0.172	CrCrCtD
Baclofen—Chlorpropamide—Glipizide—type 2 diabetes mellitus	0.0588	0.172	CrCrCtD
Baclofen—Chlorpropamide—Tolbutamide—type 2 diabetes mellitus	0.0588	0.172	CrCrCtD
Baclofen—Chlorpropamide—Glyburide—type 2 diabetes mellitus	0.0408	0.119	CrCrCtD
Baclofen—Ibuprofen—THBD—type 2 diabetes mellitus	0.000501	0.222	CrCbGaD
Baclofen—Chlorpropamide—ABCC8—type 2 diabetes mellitus	0.000475	0.21	CrCbGaD
Baclofen—Ibuprofen—PLAT—type 2 diabetes mellitus	0.000343	0.152	CrCbGaD
Baclofen—Chlorpropamide—KCNJ11—type 2 diabetes mellitus	0.000335	0.148	CrCbGaD
Baclofen—Ibuprofen—BCL2—type 2 diabetes mellitus	0.000197	0.0873	CrCbGaD
Baclofen—Ibuprofen—PPARG—type 2 diabetes mellitus	0.000109	0.0484	CrCbGaD
Baclofen—Chlorphenesin—CYP3A4—type 2 diabetes mellitus	0.000106	0.0468	CrCbGaD
Baclofen—Chlorphenesin—PTGS2—type 2 diabetes mellitus	0.000103	0.0458	CrCbGaD
Baclofen—Ibuprofen—PTGS2—type 2 diabetes mellitus	4.61e-05	0.0204	CrCbGaD
Baclofen—Dermatitis—Sitagliptin—type 2 diabetes mellitus	4.14e-05	0.000501	CcSEcCtD
Baclofen—Headache—Glimepiride—type 2 diabetes mellitus	4.13e-05	0.000499	CcSEcCtD
Baclofen—Ill-defined disorder—Losartan—type 2 diabetes mellitus	4.13e-05	0.000499	CcSEcCtD
Baclofen—SLC22A8—SLC-mediated transmembrane transport—SLC2A1—type 2 diabetes mellitus	4.13e-05	0.000997	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—CCKAR—type 2 diabetes mellitus	4.12e-05	0.000995	CbGpPWpGaD
Baclofen—Headache—Sitagliptin—type 2 diabetes mellitus	4.12e-05	0.000498	CcSEcCtD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC30A8—type 2 diabetes mellitus	4.12e-05	0.000994	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ABCC8—type 2 diabetes mellitus	4.12e-05	0.000994	CbGpPWpGaD
Baclofen—Anaemia—Losartan—type 2 diabetes mellitus	4.11e-05	0.000497	CcSEcCtD
Baclofen—Ibuprofen—ALB—type 2 diabetes mellitus	4.11e-05	0.0182	CrCbGaD
Baclofen—GABBR1—GPCR ligand binding—CCR5—type 2 diabetes mellitus	4.09e-05	0.000988	CbGpPWpGaD
Baclofen—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	4.09e-05	0.000494	CcSEcCtD
Baclofen—Agitation—Losartan—type 2 diabetes mellitus	4.09e-05	0.000494	CcSEcCtD
Baclofen—Oedema—Metformin—type 2 diabetes mellitus	4.09e-05	0.000494	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—IAPP—type 2 diabetes mellitus	4.09e-05	0.000986	CbGpPWpGaD
Baclofen—Tinnitus—Ramipril—type 2 diabetes mellitus	4.09e-05	0.000494	CcSEcCtD
Baclofen—Hypertension—Irbesartan—type 2 diabetes mellitus	4.08e-05	0.000493	CcSEcCtD
Baclofen—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	4.07e-05	0.000492	CcSEcCtD
Baclofen—Flushing—Ramipril—type 2 diabetes mellitus	4.07e-05	0.000491	CcSEcCtD
Baclofen—Infection—Metformin—type 2 diabetes mellitus	4.06e-05	0.000491	CcSEcCtD
Baclofen—Insomnia—Valsartan—type 2 diabetes mellitus	4.06e-05	0.00049	CcSEcCtD
Baclofen—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	4.04e-05	0.000488	CcSEcCtD
Baclofen—Paraesthesia—Valsartan—type 2 diabetes mellitus	4.03e-05	0.000487	CcSEcCtD
Baclofen—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	4.03e-05	0.000486	CcSEcCtD
Baclofen—Chest pain—Irbesartan—type 2 diabetes mellitus	4.02e-05	0.000486	CcSEcCtD
Baclofen—Myalgia—Irbesartan—type 2 diabetes mellitus	4.02e-05	0.000486	CcSEcCtD
Baclofen—Shock—Metformin—type 2 diabetes mellitus	4.02e-05	0.000486	CcSEcCtD
Baclofen—GABBR2—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	4.01e-05	0.000969	CbGpPWpGaD
Baclofen—Insomnia—Orlistat—type 2 diabetes mellitus	4.01e-05	0.000485	CcSEcCtD
Baclofen—Malaise—Losartan—type 2 diabetes mellitus	4.01e-05	0.000485	CcSEcCtD
Baclofen—Anxiety—Irbesartan—type 2 diabetes mellitus	4.01e-05	0.000484	CcSEcCtD
Baclofen—Nervous system disorder—Metformin—type 2 diabetes mellitus	4.01e-05	0.000484	CcSEcCtD
Baclofen—Dyspnoea—Valsartan—type 2 diabetes mellitus	4e-05	0.000483	CcSEcCtD
Baclofen—GABBR1—GPCR ligand binding—C3—type 2 diabetes mellitus	4e-05	0.000965	CbGpPWpGaD
Baclofen—Vertigo—Losartan—type 2 diabetes mellitus	4e-05	0.000483	CcSEcCtD
Baclofen—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	4e-05	0.000483	CcSEcCtD
Baclofen—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	4e-05	0.000483	CcSEcCtD
Baclofen—Somnolence—Valsartan—type 2 diabetes mellitus	3.99e-05	0.000482	CcSEcCtD
Baclofen—Syncope—Losartan—type 2 diabetes mellitus	3.99e-05	0.000482	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—TRPC6—type 2 diabetes mellitus	3.99e-05	0.000963	CbGpPWpGaD
Baclofen—Paraesthesia—Orlistat—type 2 diabetes mellitus	3.98e-05	0.000481	CcSEcCtD
Baclofen—Discomfort—Irbesartan—type 2 diabetes mellitus	3.98e-05	0.00048	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	3.98e-05	0.00096	CbGpPWpGaD
Baclofen—Skin disorder—Metformin—type 2 diabetes mellitus	3.97e-05	0.00048	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—AGTR2—type 2 diabetes mellitus	3.97e-05	0.000958	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—COX2—type 2 diabetes mellitus	3.96e-05	0.000957	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC5A2—type 2 diabetes mellitus	3.96e-05	0.000957	CbGpPWpGaD
Baclofen—SLC22A8—SLC-mediated transmembrane transport—SLC2A4—type 2 diabetes mellitus	3.96e-05	0.000955	CbGpPWpGaD
Baclofen—Hyperhidrosis—Metformin—type 2 diabetes mellitus	3.95e-05	0.000477	CcSEcCtD
Baclofen—Dyspepsia—Valsartan—type 2 diabetes mellitus	3.95e-05	0.000477	CcSEcCtD
Baclofen—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	3.95e-05	0.000477	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	3.94e-05	0.000951	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—SPRY2—type 2 diabetes mellitus	3.94e-05	0.000951	CbGpPWpGaD
Baclofen—Dizziness—Bromocriptine—type 2 diabetes mellitus	3.94e-05	0.000475	CcSEcCtD
Baclofen—Dry mouth—Irbesartan—type 2 diabetes mellitus	3.94e-05	0.000475	CcSEcCtD
Baclofen—Palpitations—Losartan—type 2 diabetes mellitus	3.93e-05	0.000475	CcSEcCtD
Baclofen—Nausea—Glimepiride—type 2 diabetes mellitus	3.92e-05	0.000473	CcSEcCtD
Baclofen—Arrhythmia—Ramipril—type 2 diabetes mellitus	3.91e-05	0.000473	CcSEcCtD
Baclofen—Loss of consciousness—Losartan—type 2 diabetes mellitus	3.91e-05	0.000472	CcSEcCtD
Baclofen—Nausea—Sitagliptin—type 2 diabetes mellitus	3.91e-05	0.000472	CcSEcCtD
Baclofen—Dyspepsia—Orlistat—type 2 diabetes mellitus	3.91e-05	0.000472	CcSEcCtD
Baclofen—Asthenia—Glyburide—type 2 diabetes mellitus	3.9e-05	0.000472	CcSEcCtD
Baclofen—Decreased appetite—Valsartan—type 2 diabetes mellitus	3.9e-05	0.000471	CcSEcCtD
Baclofen—Anorexia—Metformin—type 2 diabetes mellitus	3.9e-05	0.000471	CcSEcCtD
Baclofen—SLC22A8—Transmembrane transport of small molecules—NCOA6—type 2 diabetes mellitus	3.89e-05	0.00094	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—GNB3—type 2 diabetes mellitus	3.88e-05	0.000938	CbGpPWpGaD
Baclofen—Urticaria—Gliclazide—type 2 diabetes mellitus	3.88e-05	0.000469	CcSEcCtD
Baclofen—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	3.88e-05	0.000468	CcSEcCtD
Baclofen—Alopecia—Ramipril—type 2 diabetes mellitus	3.87e-05	0.000468	CcSEcCtD
Baclofen—Fatigue—Valsartan—type 2 diabetes mellitus	3.87e-05	0.000468	CcSEcCtD
Baclofen—Abdominal pain—Gliclazide—type 2 diabetes mellitus	3.86e-05	0.000467	CcSEcCtD
Baclofen—Body temperature increased—Gliclazide—type 2 diabetes mellitus	3.86e-05	0.000467	CcSEcCtD
Baclofen—Oedema—Irbesartan—type 2 diabetes mellitus	3.86e-05	0.000466	CcSEcCtD
Baclofen—Decreased appetite—Orlistat—type 2 diabetes mellitus	3.86e-05	0.000466	CcSEcCtD
Baclofen—Pruritus—Glyburide—type 2 diabetes mellitus	3.85e-05	0.000465	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—RBP4—type 2 diabetes mellitus	3.84e-05	0.000927	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—GIPR—type 2 diabetes mellitus	3.84e-05	0.000927	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—GRK5—type 2 diabetes mellitus	3.84e-05	0.000927	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—GLP1R—type 2 diabetes mellitus	3.84e-05	0.000927	CbGpPWpGaD
Baclofen—Mental disorder—Ramipril—type 2 diabetes mellitus	3.84e-05	0.000464	CcSEcCtD
Baclofen—Constipation—Valsartan—type 2 diabetes mellitus	3.84e-05	0.000464	CcSEcCtD
Baclofen—Infection—Irbesartan—type 2 diabetes mellitus	3.83e-05	0.000463	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—MMP3—type 2 diabetes mellitus	3.83e-05	0.000925	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—AVP—type 2 diabetes mellitus	3.83e-05	0.000925	CbGpPWpGaD
Baclofen—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	3.83e-05	0.000463	CcSEcCtD
Baclofen—Fatigue—Orlistat—type 2 diabetes mellitus	3.82e-05	0.000462	CcSEcCtD
Baclofen—Hypotension—Metformin—type 2 diabetes mellitus	3.82e-05	0.000461	CcSEcCtD
Baclofen—Malnutrition—Ramipril—type 2 diabetes mellitus	3.81e-05	0.000461	CcSEcCtD
Baclofen—GABBR2—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	3.81e-05	0.00092	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—EDNRB—type 2 diabetes mellitus	3.8e-05	0.000917	CbGpPWpGaD
Baclofen—GABBR1—GPCR ligand binding—AGT—type 2 diabetes mellitus	3.8e-05	0.000917	CbGpPWpGaD
Baclofen—Shock—Irbesartan—type 2 diabetes mellitus	3.8e-05	0.000458	CcSEcCtD
Baclofen—Pain—Orlistat—type 2 diabetes mellitus	3.79e-05	0.000458	CcSEcCtD
Baclofen—Chest pain—Losartan—type 2 diabetes mellitus	3.79e-05	0.000458	CcSEcCtD
Baclofen—Myalgia—Losartan—type 2 diabetes mellitus	3.79e-05	0.000458	CcSEcCtD
Baclofen—Vomiting—Bromocriptine—type 2 diabetes mellitus	3.79e-05	0.000457	CcSEcCtD
Baclofen—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	3.78e-05	0.000457	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—CCKAR—type 2 diabetes mellitus	3.78e-05	0.000912	CbGpPWpGaD
Baclofen—Anxiety—Losartan—type 2 diabetes mellitus	3.77e-05	0.000456	CcSEcCtD
Baclofen—Tachycardia—Irbesartan—type 2 diabetes mellitus	3.77e-05	0.000455	CcSEcCtD
Baclofen—Rash—Bromocriptine—type 2 diabetes mellitus	3.75e-05	0.000453	CcSEcCtD
Baclofen—Dermatitis—Bromocriptine—type 2 diabetes mellitus	3.75e-05	0.000453	CcSEcCtD
Baclofen—Skin disorder—Irbesartan—type 2 diabetes mellitus	3.75e-05	0.000453	CcSEcCtD
Baclofen—Discomfort—Losartan—type 2 diabetes mellitus	3.74e-05	0.000452	CcSEcCtD
Baclofen—Dysgeusia—Ramipril—type 2 diabetes mellitus	3.74e-05	0.000451	CcSEcCtD
Baclofen—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	3.73e-05	0.000451	CcSEcCtD
Baclofen—Headache—Bromocriptine—type 2 diabetes mellitus	3.73e-05	0.00045	CcSEcCtD
Baclofen—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	3.72e-05	0.00045	CcSEcCtD
Baclofen—Diarrhoea—Glyburide—type 2 diabetes mellitus	3.72e-05	0.00045	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—IAPP—type 2 diabetes mellitus	3.71e-05	0.000896	CbGpPWpGaD
Baclofen—Dry mouth—Losartan—type 2 diabetes mellitus	3.7e-05	0.000447	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—HTR2C—type 2 diabetes mellitus	3.69e-05	0.00089	CbGpPWpGaD
Baclofen—Anorexia—Irbesartan—type 2 diabetes mellitus	3.68e-05	0.000444	CcSEcCtD
Baclofen—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	3.67e-05	0.000443	CcSEcCtD
Baclofen—Paraesthesia—Metformin—type 2 diabetes mellitus	3.67e-05	0.000443	CcSEcCtD
Baclofen—Confusional state—Losartan—type 2 diabetes mellitus	3.66e-05	0.000442	CcSEcCtD
Baclofen—Feeling abnormal—Orlistat—type 2 diabetes mellitus	3.66e-05	0.000442	CcSEcCtD
Baclofen—Dyspnoea—Metformin—type 2 diabetes mellitus	3.65e-05	0.00044	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—EDN1—type 2 diabetes mellitus	3.64e-05	0.00088	CbGpPWpGaD
Baclofen—Somnolence—Metformin—type 2 diabetes mellitus	3.63e-05	0.000439	CcSEcCtD
Baclofen—Oedema—Losartan—type 2 diabetes mellitus	3.63e-05	0.000439	CcSEcCtD
Baclofen—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	3.63e-05	0.000438	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—TRPC6—type 2 diabetes mellitus	3.62e-05	0.000875	CbGpPWpGaD
Baclofen—Infection—Losartan—type 2 diabetes mellitus	3.61e-05	0.000436	CcSEcCtD
Baclofen—Hypotension—Irbesartan—type 2 diabetes mellitus	3.61e-05	0.000435	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—AGTR2—type 2 diabetes mellitus	3.6e-05	0.00087	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ATP2A3—type 2 diabetes mellitus	3.6e-05	0.000869	CbGpPWpGaD
Baclofen—Dyspepsia—Metformin—type 2 diabetes mellitus	3.6e-05	0.000435	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—EDNRA—type 2 diabetes mellitus	3.59e-05	0.000866	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	3.59e-05	0.000866	CbGpPWpGaD
Baclofen—Tremor—Ramipril—type 2 diabetes mellitus	3.57e-05	0.000432	CcSEcCtD
Baclofen—Shock—Losartan—type 2 diabetes mellitus	3.57e-05	0.000431	CcSEcCtD
Baclofen—Urticaria—Valsartan—type 2 diabetes mellitus	3.57e-05	0.000431	CcSEcCtD
Baclofen—Nervous system disorder—Losartan—type 2 diabetes mellitus	3.56e-05	0.00043	CcSEcCtD
Baclofen—Decreased appetite—Metformin—type 2 diabetes mellitus	3.55e-05	0.000429	CcSEcCtD
Baclofen—Abdominal pain—Valsartan—type 2 diabetes mellitus	3.55e-05	0.000429	CcSEcCtD
Baclofen—Tachycardia—Losartan—type 2 diabetes mellitus	3.54e-05	0.000428	CcSEcCtD
Baclofen—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	3.54e-05	0.000428	CcSEcCtD
Baclofen—Nausea—Bromocriptine—type 2 diabetes mellitus	3.54e-05	0.000427	CcSEcCtD
Baclofen—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	3.53e-05	0.000426	CcSEcCtD
Baclofen—Fatigue—Metformin—type 2 diabetes mellitus	3.52e-05	0.000426	CcSEcCtD
Baclofen—Urticaria—Orlistat—type 2 diabetes mellitus	3.52e-05	0.000426	CcSEcCtD
Baclofen—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	3.52e-05	0.000425	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—MC4R—type 2 diabetes mellitus	3.51e-05	0.000848	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—ADRA2A—type 2 diabetes mellitus	3.51e-05	0.000848	CbGpPWpGaD
Baclofen—Hyperhidrosis—Losartan—type 2 diabetes mellitus	3.51e-05	0.000424	CcSEcCtD
Baclofen—Body temperature increased—Orlistat—type 2 diabetes mellitus	3.51e-05	0.000424	CcSEcCtD
Baclofen—Abdominal pain—Orlistat—type 2 diabetes mellitus	3.51e-05	0.000424	CcSEcCtD
Baclofen—Asthenia—Gliclazide—type 2 diabetes mellitus	3.51e-05	0.000423	CcSEcCtD
Baclofen—Agitation—Ramipril—type 2 diabetes mellitus	3.51e-05	0.000423	CcSEcCtD
Baclofen—GABBR2—GPCR downstream signaling—C3—type 2 diabetes mellitus	3.51e-05	0.000846	CbGpPWpGaD
Baclofen—Constipation—Metformin—type 2 diabetes mellitus	3.5e-05	0.000422	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	3.5e-05	0.000844	CbGpPWpGaD
Baclofen—Paraesthesia—Irbesartan—type 2 diabetes mellitus	3.46e-05	0.000418	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	3.46e-05	0.000836	CbGpPWpGaD
Baclofen—Anorexia—Losartan—type 2 diabetes mellitus	3.46e-05	0.000418	CcSEcCtD
Baclofen—Vomiting—Glyburide—type 2 diabetes mellitus	3.46e-05	0.000418	CcSEcCtD
Baclofen—Pruritus—Gliclazide—type 2 diabetes mellitus	3.46e-05	0.000418	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	3.45e-05	0.000834	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	3.45e-05	0.000833	CbGpPWpGaD
Baclofen—Malaise—Ramipril—type 2 diabetes mellitus	3.44e-05	0.000416	CcSEcCtD
Baclofen—Dyspnoea—Irbesartan—type 2 diabetes mellitus	3.44e-05	0.000415	CcSEcCtD
Baclofen—Rash—Glyburide—type 2 diabetes mellitus	3.43e-05	0.000414	CcSEcCtD
Baclofen—Somnolence—Irbesartan—type 2 diabetes mellitus	3.43e-05	0.000414	CcSEcCtD
Baclofen—Dermatitis—Glyburide—type 2 diabetes mellitus	3.43e-05	0.000414	CcSEcCtD
Baclofen—Vertigo—Ramipril—type 2 diabetes mellitus	3.43e-05	0.000414	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	3.42e-05	0.000826	CbGpPWpGaD
Baclofen—Syncope—Ramipril—type 2 diabetes mellitus	3.42e-05	0.000413	CcSEcCtD
Baclofen—Headache—Glyburide—type 2 diabetes mellitus	3.41e-05	0.000412	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—IAPP—type 2 diabetes mellitus	3.4e-05	0.000821	CbGpPWpGaD
Baclofen—Dyspepsia—Irbesartan—type 2 diabetes mellitus	3.4e-05	0.00041	CcSEcCtD
Baclofen—Hypotension—Losartan—type 2 diabetes mellitus	3.39e-05	0.00041	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—INSR—type 2 diabetes mellitus	3.38e-05	0.000816	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—GIP—type 2 diabetes mellitus	3.38e-05	0.000816	CbGpPWpGaD
Baclofen—Palpitations—Ramipril—type 2 diabetes mellitus	3.37e-05	0.000407	CcSEcCtD
Baclofen—SLC22A8—Transmembrane transport of small molecules—HK1—type 2 diabetes mellitus	3.37e-05	0.000814	CbGpPWpGaD
Baclofen—Feeling abnormal—Metformin—type 2 diabetes mellitus	3.37e-05	0.000407	CcSEcCtD
Baclofen—SLC22A8—SLC-mediated transmembrane transport—AVP—type 2 diabetes mellitus	3.36e-05	0.000812	CbGpPWpGaD
Baclofen—Decreased appetite—Irbesartan—type 2 diabetes mellitus	3.35e-05	0.000405	CcSEcCtD
Baclofen—Loss of consciousness—Ramipril—type 2 diabetes mellitus	3.35e-05	0.000405	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	3.35e-05	0.000808	CbGpPWpGaD
Baclofen—Diarrhoea—Gliclazide—type 2 diabetes mellitus	3.34e-05	0.000404	CcSEcCtD
Baclofen—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	3.34e-05	0.000404	CcSEcCtD
Baclofen—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	3.33e-05	0.000402	CcSEcCtD
Baclofen—GABBR2—GPCR downstream signaling—AGT—type 2 diabetes mellitus	3.33e-05	0.000804	CbGpPWpGaD
Baclofen—Fatigue—Irbesartan—type 2 diabetes mellitus	3.33e-05	0.000402	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—TRPC6—type 2 diabetes mellitus	3.32e-05	0.000802	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	3.32e-05	0.000801	CbGpPWpGaD
Baclofen—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	3.31e-05	0.0004	CcSEcCtD
Baclofen—Convulsion—Ramipril—type 2 diabetes mellitus	3.31e-05	0.000399	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—AGTR2—type 2 diabetes mellitus	3.3e-05	0.000797	CbGpPWpGaD
Baclofen—Constipation—Irbesartan—type 2 diabetes mellitus	3.3e-05	0.000399	CcSEcCtD
Baclofen—Pain—Irbesartan—type 2 diabetes mellitus	3.3e-05	0.000399	CcSEcCtD
Baclofen—Insomnia—Losartan—type 2 diabetes mellitus	3.28e-05	0.000397	CcSEcCtD
Baclofen—Paraesthesia—Losartan—type 2 diabetes mellitus	3.26e-05	0.000394	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—CCR5—type 2 diabetes mellitus	3.26e-05	0.000786	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	3.26e-05	0.000786	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—GCKR—type 2 diabetes mellitus	3.26e-05	0.000786	CbGpPWpGaD
Baclofen—Urticaria—Metformin—type 2 diabetes mellitus	3.25e-05	0.000392	CcSEcCtD
Baclofen—Myalgia—Ramipril—type 2 diabetes mellitus	3.25e-05	0.000392	CcSEcCtD
Baclofen—Chest pain—Ramipril—type 2 diabetes mellitus	3.25e-05	0.000392	CcSEcCtD
Baclofen—Dyspnoea—Losartan—type 2 diabetes mellitus	3.24e-05	0.000391	CcSEcCtD
Baclofen—Anxiety—Ramipril—type 2 diabetes mellitus	3.24e-05	0.000391	CcSEcCtD
Baclofen—Nausea—Glyburide—type 2 diabetes mellitus	3.23e-05	0.00039	CcSEcCtD
Baclofen—Abdominal pain—Metformin—type 2 diabetes mellitus	3.23e-05	0.00039	CcSEcCtD
Baclofen—Dizziness—Gliclazide—type 2 diabetes mellitus	3.23e-05	0.00039	CcSEcCtD
Baclofen—Somnolence—Losartan—type 2 diabetes mellitus	3.23e-05	0.00039	CcSEcCtD
Baclofen—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	3.23e-05	0.00039	CcSEcCtD
Baclofen—Asthenia—Valsartan—type 2 diabetes mellitus	3.22e-05	0.000389	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—LEPR—type 2 diabetes mellitus	3.21e-05	0.000776	CbGpPWpGaD
Baclofen—Discomfort—Ramipril—type 2 diabetes mellitus	3.21e-05	0.000388	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—GCG—type 2 diabetes mellitus	3.2e-05	0.000772	CbGpPWpGaD
Baclofen—Dyspepsia—Losartan—type 2 diabetes mellitus	3.2e-05	0.000386	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	3.19e-05	0.00077	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—C3—type 2 diabetes mellitus	3.18e-05	0.000769	CbGpPWpGaD
Baclofen—Asthenia—Orlistat—type 2 diabetes mellitus	3.18e-05	0.000384	CcSEcCtD
Baclofen—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	3.18e-05	0.000384	CcSEcCtD
Baclofen—Pruritus—Valsartan—type 2 diabetes mellitus	3.18e-05	0.000384	CcSEcCtD
Baclofen—Dry mouth—Ramipril—type 2 diabetes mellitus	3.18e-05	0.000384	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—GHRL—type 2 diabetes mellitus	3.17e-05	0.000766	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—EDNRB—type 2 diabetes mellitus	3.16e-05	0.000763	CbGpPWpGaD
Baclofen—Decreased appetite—Losartan—type 2 diabetes mellitus	3.16e-05	0.000381	CcSEcCtD
Baclofen—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	3.16e-05	0.000381	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	3.15e-05	0.000759	CbGpPWpGaD
Baclofen—Confusional state—Ramipril—type 2 diabetes mellitus	3.14e-05	0.000379	CcSEcCtD
Baclofen—Pruritus—Orlistat—type 2 diabetes mellitus	3.14e-05	0.000379	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—CALCA—type 2 diabetes mellitus	3.14e-05	0.000757	CbGpPWpGaD
Baclofen—Fatigue—Losartan—type 2 diabetes mellitus	3.13e-05	0.000378	CcSEcCtD
Baclofen—GABBR1—GPCR ligand binding—CCL2—type 2 diabetes mellitus	3.13e-05	0.000755	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ABCC2—type 2 diabetes mellitus	3.12e-05	0.000753	CbGpPWpGaD
Baclofen—Oedema—Ramipril—type 2 diabetes mellitus	3.11e-05	0.000376	CcSEcCtD
Baclofen—Vomiting—Gliclazide—type 2 diabetes mellitus	3.11e-05	0.000375	CcSEcCtD
Baclofen—Pain—Losartan—type 2 diabetes mellitus	3.11e-05	0.000375	CcSEcCtD
Baclofen—Constipation—Losartan—type 2 diabetes mellitus	3.11e-05	0.000375	CcSEcCtD
Baclofen—Rash—Gliclazide—type 2 diabetes mellitus	3.08e-05	0.000372	CcSEcCtD
Baclofen—Dermatitis—Gliclazide—type 2 diabetes mellitus	3.08e-05	0.000372	CcSEcCtD
Baclofen—GABBR2—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	3.08e-05	0.000743	CbGpPWpGaD
Baclofen—Diarrhoea—Valsartan—type 2 diabetes mellitus	3.07e-05	0.000371	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—HTR2C—type 2 diabetes mellitus	3.07e-05	0.000741	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PSMD6—type 2 diabetes mellitus	3.07e-05	0.000741	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	3.07e-05	0.000741	CbGpPWpGaD
Baclofen—Urticaria—Irbesartan—type 2 diabetes mellitus	3.07e-05	0.00037	CcSEcCtD
Baclofen—Shock—Ramipril—type 2 diabetes mellitus	3.06e-05	0.00037	CcSEcCtD
Baclofen—Headache—Gliclazide—type 2 diabetes mellitus	3.06e-05	0.00037	CcSEcCtD
Baclofen—Nervous system disorder—Ramipril—type 2 diabetes mellitus	3.05e-05	0.000369	CcSEcCtD
Baclofen—Body temperature increased—Irbesartan—type 2 diabetes mellitus	3.05e-05	0.000368	CcSEcCtD
Baclofen—Abdominal pain—Irbesartan—type 2 diabetes mellitus	3.05e-05	0.000368	CcSEcCtD
Baclofen—Tachycardia—Ramipril—type 2 diabetes mellitus	3.04e-05	0.000367	CcSEcCtD
Baclofen—Diarrhoea—Orlistat—type 2 diabetes mellitus	3.04e-05	0.000367	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—AGT—type 2 diabetes mellitus	3.02e-05	0.00073	CbGpPWpGaD
Baclofen—Skin disorder—Ramipril—type 2 diabetes mellitus	3.02e-05	0.000365	CcSEcCtD
Baclofen—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	3.01e-05	0.000364	CcSEcCtD
Baclofen—Feeling abnormal—Losartan—type 2 diabetes mellitus	2.99e-05	0.000361	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—TLE4—type 2 diabetes mellitus	2.99e-05	0.000721	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—EDNRA—type 2 diabetes mellitus	2.99e-05	0.000721	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—CALM1—type 2 diabetes mellitus	2.97e-05	0.000718	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CYBA—type 2 diabetes mellitus	2.97e-05	0.000718	CbGpPWpGaD
Baclofen—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	2.97e-05	0.000359	CcSEcCtD
Baclofen—Dizziness—Valsartan—type 2 diabetes mellitus	2.97e-05	0.000359	CcSEcCtD
Baclofen—Anorexia—Ramipril—type 2 diabetes mellitus	2.97e-05	0.000358	CcSEcCtD
Baclofen—Dizziness—Orlistat—type 2 diabetes mellitus	2.93e-05	0.000354	CcSEcCtD
Baclofen—Asthenia—Metformin—type 2 diabetes mellitus	2.93e-05	0.000354	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	2.92e-05	0.000706	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—GHRL—type 2 diabetes mellitus	2.91e-05	0.000703	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PLAT—type 2 diabetes mellitus	2.91e-05	0.000703	CbGpPWpGaD
Baclofen—Hypotension—Ramipril—type 2 diabetes mellitus	2.91e-05	0.000351	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—GCG—type 2 diabetes mellitus	2.9e-05	0.000701	CbGpPWpGaD
Baclofen—Nausea—Gliclazide—type 2 diabetes mellitus	2.9e-05	0.000351	CcSEcCtD
Baclofen—Pruritus—Metformin—type 2 diabetes mellitus	2.89e-05	0.000349	CcSEcCtD
Baclofen—Urticaria—Losartan—type 2 diabetes mellitus	2.88e-05	0.000348	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—ADRB3—type 2 diabetes mellitus	2.87e-05	0.000694	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CALCA—type 2 diabetes mellitus	2.87e-05	0.000694	CbGpPWpGaD
Baclofen—Abdominal pain—Losartan—type 2 diabetes mellitus	2.87e-05	0.000347	CcSEcCtD
Baclofen—Body temperature increased—Losartan—type 2 diabetes mellitus	2.87e-05	0.000347	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	2.86e-05	0.00069	CbGpPWpGaD
Baclofen—Vomiting—Valsartan—type 2 diabetes mellitus	2.85e-05	0.000345	CcSEcCtD
Baclofen—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	2.84e-05	0.000343	CcSEcCtD
Baclofen—Rash—Valsartan—type 2 diabetes mellitus	2.83e-05	0.000342	CcSEcCtD
Baclofen—Dermatitis—Valsartan—type 2 diabetes mellitus	2.83e-05	0.000342	CcSEcCtD
Baclofen—Vomiting—Orlistat—type 2 diabetes mellitus	2.82e-05	0.000341	CcSEcCtD
Baclofen—Insomnia—Ramipril—type 2 diabetes mellitus	2.82e-05	0.00034	CcSEcCtD
Baclofen—Headache—Valsartan—type 2 diabetes mellitus	2.81e-05	0.00034	CcSEcCtD
Baclofen—Diarrhoea—Metformin—type 2 diabetes mellitus	2.8e-05	0.000338	CcSEcCtD
Baclofen—Rash—Orlistat—type 2 diabetes mellitus	2.8e-05	0.000338	CcSEcCtD
Baclofen—Paraesthesia—Ramipril—type 2 diabetes mellitus	2.8e-05	0.000338	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	2.79e-05	0.000675	CbGpPWpGaD
Baclofen—Dermatitis—Orlistat—type 2 diabetes mellitus	2.79e-05	0.000338	CcSEcCtD
Baclofen—Headache—Orlistat—type 2 diabetes mellitus	2.78e-05	0.000336	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—CRHR1—type 2 diabetes mellitus	2.78e-05	0.00067	CbGpPWpGaD
Baclofen—Dyspnoea—Ramipril—type 2 diabetes mellitus	2.78e-05	0.000335	CcSEcCtD
Baclofen—Asthenia—Irbesartan—type 2 diabetes mellitus	2.77e-05	0.000334	CcSEcCtD
Baclofen—Somnolence—Ramipril—type 2 diabetes mellitus	2.77e-05	0.000334	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	2.76e-05	0.000665	CbGpPWpGaD
Baclofen—Dyspepsia—Ramipril—type 2 diabetes mellitus	2.74e-05	0.000331	CcSEcCtD
Baclofen—Pruritus—Irbesartan—type 2 diabetes mellitus	2.73e-05	0.00033	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—AVP—type 2 diabetes mellitus	2.72e-05	0.000656	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC2A2—type 2 diabetes mellitus	2.71e-05	0.000654	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	2.71e-05	0.000654	CbGpPWpGaD
Baclofen—Decreased appetite—Ramipril—type 2 diabetes mellitus	2.71e-05	0.000327	CcSEcCtD
Baclofen—Dizziness—Metformin—type 2 diabetes mellitus	2.7e-05	0.000327	CcSEcCtD
Baclofen—GABBR2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	2.69e-05	0.000651	CbGpPWpGaD
Baclofen—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	2.69e-05	0.000325	CcSEcCtD
Baclofen—Fatigue—Ramipril—type 2 diabetes mellitus	2.68e-05	0.000324	CcSEcCtD
Baclofen—Nausea—Valsartan—type 2 diabetes mellitus	2.67e-05	0.000322	CcSEcCtD
Baclofen—Constipation—Ramipril—type 2 diabetes mellitus	2.66e-05	0.000322	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—GCG—type 2 diabetes mellitus	2.66e-05	0.000643	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	2.66e-05	0.000643	CbGpPWpGaD
Baclofen—Diarrhoea—Irbesartan—type 2 diabetes mellitus	2.64e-05	0.000319	CcSEcCtD
Baclofen—Nausea—Orlistat—type 2 diabetes mellitus	2.64e-05	0.000318	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	2.62e-05	0.000632	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	2.61e-05	0.00063	CbGpPWpGaD
Baclofen—Asthenia—Losartan—type 2 diabetes mellitus	2.61e-05	0.000315	CcSEcCtD
Baclofen—Vomiting—Metformin—type 2 diabetes mellitus	2.6e-05	0.000314	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	2.59e-05	0.000624	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ATP2A2—type 2 diabetes mellitus	2.59e-05	0.000624	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—GCK—type 2 diabetes mellitus	2.59e-05	0.000624	CbGpPWpGaD
Baclofen—Rash—Metformin—type 2 diabetes mellitus	2.58e-05	0.000311	CcSEcCtD
Baclofen—Dermatitis—Metformin—type 2 diabetes mellitus	2.58e-05	0.000311	CcSEcCtD
Baclofen—Pruritus—Losartan—type 2 diabetes mellitus	2.57e-05	0.00031	CcSEcCtD
Baclofen—Feeling abnormal—Ramipril—type 2 diabetes mellitus	2.57e-05	0.00031	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	2.56e-05	0.000619	CbGpPWpGaD
Baclofen—Headache—Metformin—type 2 diabetes mellitus	2.56e-05	0.000309	CcSEcCtD
Baclofen—Dizziness—Irbesartan—type 2 diabetes mellitus	2.55e-05	0.000308	CcSEcCtD
Baclofen—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	2.55e-05	0.000308	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—SPRY2—type 2 diabetes mellitus	2.54e-05	0.000613	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	2.54e-05	0.000613	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC9A1—type 2 diabetes mellitus	2.52e-05	0.000609	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—TRPC6—type 2 diabetes mellitus	2.51e-05	0.000606	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—GNB3—type 2 diabetes mellitus	2.5e-05	0.000604	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—CETP—type 2 diabetes mellitus	2.49e-05	0.000602	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	2.49e-05	0.000601	CbGpPWpGaD
Baclofen—Diarrhoea—Losartan—type 2 diabetes mellitus	2.48e-05	0.0003	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—RBP4—type 2 diabetes mellitus	2.47e-05	0.000597	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—GLP1R—type 2 diabetes mellitus	2.47e-05	0.000597	CbGpPWpGaD
Baclofen—Urticaria—Ramipril—type 2 diabetes mellitus	2.47e-05	0.000299	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—MMP3—type 2 diabetes mellitus	2.47e-05	0.000596	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—AVP—type 2 diabetes mellitus	2.47e-05	0.000596	CbGpPWpGaD
Baclofen—Body temperature increased—Ramipril—type 2 diabetes mellitus	2.46e-05	0.000297	CcSEcCtD
Baclofen—Abdominal pain—Ramipril—type 2 diabetes mellitus	2.46e-05	0.000297	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	2.46e-05	0.000593	CbGpPWpGaD
Baclofen—Vomiting—Irbesartan—type 2 diabetes mellitus	2.45e-05	0.000296	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	2.45e-05	0.000591	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	2.45e-05	0.00059	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CCKAR—type 2 diabetes mellitus	2.43e-05	0.000588	CbGpPWpGaD
Baclofen—Rash—Irbesartan—type 2 diabetes mellitus	2.43e-05	0.000294	CcSEcCtD
Baclofen—Dermatitis—Irbesartan—type 2 diabetes mellitus	2.43e-05	0.000294	CcSEcCtD
Baclofen—Nausea—Metformin—type 2 diabetes mellitus	2.43e-05	0.000293	CcSEcCtD
Baclofen—Headache—Irbesartan—type 2 diabetes mellitus	2.42e-05	0.000292	CcSEcCtD
Baclofen—Dizziness—Losartan—type 2 diabetes mellitus	2.4e-05	0.00029	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—EDN1—type 2 diabetes mellitus	2.35e-05	0.000567	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	2.32e-05	0.000559	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	2.31e-05	0.000558	CbGpPWpGaD
Baclofen—Vomiting—Losartan—type 2 diabetes mellitus	2.31e-05	0.000279	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—GNB3—type 2 diabetes mellitus	2.29e-05	0.000554	CbGpPWpGaD
Baclofen—Nausea—Irbesartan—type 2 diabetes mellitus	2.29e-05	0.000277	CcSEcCtD
Baclofen—Rash—Losartan—type 2 diabetes mellitus	2.29e-05	0.000277	CcSEcCtD
Baclofen—Dermatitis—Losartan—type 2 diabetes mellitus	2.29e-05	0.000276	CcSEcCtD
Baclofen—Headache—Losartan—type 2 diabetes mellitus	2.27e-05	0.000275	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—AVP—type 2 diabetes mellitus	2.26e-05	0.000546	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—MMP3—type 2 diabetes mellitus	2.26e-05	0.000546	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—C3—type 2 diabetes mellitus	2.26e-05	0.000545	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—IGF2—type 2 diabetes mellitus	2.25e-05	0.000544	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2.24e-05	0.000542	CbGpPWpGaD
Baclofen—Asthenia—Ramipril—type 2 diabetes mellitus	2.23e-05	0.00027	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	2.23e-05	0.000539	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	2.22e-05	0.000536	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	2.21e-05	0.000532	CbGpPWpGaD
Baclofen—Pruritus—Ramipril—type 2 diabetes mellitus	2.2e-05	0.000266	CcSEcCtD
Baclofen—SLC22A8—Transmembrane transport of small molecules—PLAT—type 2 diabetes mellitus	2.2e-05	0.000531	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—IAPP—type 2 diabetes mellitus	2.19e-05	0.000529	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—APOB—type 2 diabetes mellitus	2.19e-05	0.000528	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—INSR—type 2 diabetes mellitus	2.18e-05	0.000526	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	2.18e-05	0.000526	CbGpPWpGaD
Baclofen—Nausea—Losartan—type 2 diabetes mellitus	2.16e-05	0.000261	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.15e-05	0.00052	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—AGT—type 2 diabetes mellitus	2.15e-05	0.000518	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	2.14e-05	0.000517	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	2.14e-05	0.000516	CbGpPWpGaD
Baclofen—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.13e-05	0.000257	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	2.13e-05	0.000514	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	2.1e-05	0.000507	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC2A1—type 2 diabetes mellitus	2.1e-05	0.000506	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—LPL—type 2 diabetes mellitus	2.09e-05	0.000504	CbGpPWpGaD
Baclofen—Dizziness—Ramipril—type 2 diabetes mellitus	2.06e-05	0.000249	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—C3—type 2 diabetes mellitus	2.05e-05	0.000495	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.04e-05	0.000494	CbGpPWpGaD
Baclofen—SLC22A8—SLC-mediated transmembrane transport—ALB—type 2 diabetes mellitus	2.04e-05	0.000492	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	2.04e-05	0.000492	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC2A4—type 2 diabetes mellitus	2.01e-05	0.000485	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.98e-05	0.000479	CbGpPWpGaD
Baclofen—Vomiting—Ramipril—type 2 diabetes mellitus	1.98e-05	0.000239	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.98e-05	0.000478	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.98e-05	0.000478	CbGpPWpGaD
Baclofen—Rash—Ramipril—type 2 diabetes mellitus	1.96e-05	0.000237	CcSEcCtD
Baclofen—Dermatitis—Ramipril—type 2 diabetes mellitus	1.96e-05	0.000237	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.96e-05	0.000473	CbGpPWpGaD
Baclofen—Headache—Ramipril—type 2 diabetes mellitus	1.95e-05	0.000236	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.95e-05	0.000471	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.92e-05	0.000465	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.92e-05	0.000465	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.92e-05	0.000463	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.92e-05	0.000463	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.88e-05	0.000455	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—C3—type 2 diabetes mellitus	1.88e-05	0.000454	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.88e-05	0.000453	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.88e-05	0.000453	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.85e-05	0.000447	CbGpPWpGaD
Baclofen—Nausea—Ramipril—type 2 diabetes mellitus	1.85e-05	0.000223	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.8e-05	0.000435	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.79e-05	0.000433	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.79e-05	0.000432	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—AGT—type 2 diabetes mellitus	1.79e-05	0.000431	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.76e-05	0.000424	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—LEP—type 2 diabetes mellitus	1.75e-05	0.000423	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—APOE—type 2 diabetes mellitus	1.75e-05	0.000423	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.74e-05	0.000421	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.74e-05	0.000419	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	1.73e-05	0.000418	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.73e-05	0.000418	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	1.73e-05	0.000417	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.72e-05	0.000414	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—GCG—type 2 diabetes mellitus	1.72e-05	0.000414	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	1.71e-05	0.000413	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.69e-05	0.000407	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.68e-05	0.000406	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	1.65e-05	0.000399	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.65e-05	0.000399	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.61e-05	0.000388	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.58e-05	0.000381	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.58e-05	0.00038	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.56e-05	0.000377	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	1.54e-05	0.000373	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—INS—type 2 diabetes mellitus	1.5e-05	0.000361	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.49e-05	0.00036	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.48e-05	0.000357	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.47e-05	0.000355	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—AVP—type 2 diabetes mellitus	1.46e-05	0.000352	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.46e-05	0.000352	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.45e-05	0.000351	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.45e-05	0.000349	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.45e-05	0.000349	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.45e-05	0.000349	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.44e-05	0.000348	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.43e-05	0.000345	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—APOB—type 2 diabetes mellitus	1.41e-05	0.00034	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.4e-05	0.000339	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	1.39e-05	0.000337	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.39e-05	0.000335	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.37e-05	0.000332	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—LPL—type 2 diabetes mellitus	1.35e-05	0.000325	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.32e-05	0.000318	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.31e-05	0.000317	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.31e-05	0.000317	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	1.31e-05	0.000316	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.26e-05	0.000305	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.24e-05	0.000299	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.23e-05	0.000298	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—C3—type 2 diabetes mellitus	1.21e-05	0.000293	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.16e-05	0.000279	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.15e-05	0.000278	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—AGT—type 2 diabetes mellitus	1.15e-05	0.000278	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.13e-05	0.000273	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—LEP—type 2 diabetes mellitus	1.13e-05	0.000272	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—APOE—type 2 diabetes mellitus	1.13e-05	0.000272	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.12e-05	0.000271	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.12e-05	0.000269	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.11e-05	0.000269	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.11e-05	0.000267	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.06e-05	0.000257	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.05e-05	0.000254	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.04e-05	0.000251	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	1.04e-05	0.00025	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.02e-05	0.000246	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.01e-05	0.000243	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—SRC—type 2 diabetes mellitus	9.7e-06	0.000234	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—INS—type 2 diabetes mellitus	9.64e-06	0.000233	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CCL2—type 2 diabetes mellitus	9.48e-06	0.000229	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.45e-06	0.000228	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—IGF1—type 2 diabetes mellitus	9.32e-06	0.000225	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—AKT2—type 2 diabetes mellitus	9.32e-06	0.000225	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	9.28e-06	0.000224	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.85e-06	0.000214	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.67e-06	0.000209	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.5e-06	0.000205	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	8.45e-06	0.000204	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—NOS3—type 2 diabetes mellitus	8.45e-06	0.000204	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—RELA—type 2 diabetes mellitus	7.96e-06	0.000192	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	7.24e-06	0.000175	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.18e-06	0.000173	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—IL6—type 2 diabetes mellitus	7.13e-06	0.000172	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.78e-06	0.000164	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.71e-06	0.000162	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.58e-06	0.000159	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—IL6—type 2 diabetes mellitus	6.54e-06	0.000158	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—SRC—type 2 diabetes mellitus	6.25e-06	0.000151	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.09e-06	0.000147	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.03e-06	0.000146	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.59e-06	0.000135	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.48e-06	0.000132	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—IL6—type 2 diabetes mellitus	4.21e-06	0.000102	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.89e-06	9.38e-05	CbGpPWpGaD
